全文获取类型
| 收费全文 | 23494篇 |
| 免费 | 1676篇 |
| 国内免费 | 145篇 |
专业分类
| 耳鼻咽喉 | 200篇 |
| 儿科学 | 836篇 |
| 妇产科学 | 634篇 |
| 基础医学 | 3128篇 |
| 口腔科学 | 404篇 |
| 临床医学 | 2481篇 |
| 内科学 | 4812篇 |
| 皮肤病学 | 530篇 |
| 神经病学 | 2626篇 |
| 特种医学 | 499篇 |
| 外科学 | 2164篇 |
| 综合类 | 151篇 |
| 一般理论 | 37篇 |
| 预防医学 | 3043篇 |
| 眼科学 | 293篇 |
| 药学 | 1449篇 |
| 1篇 | |
| 中国医学 | 40篇 |
| 肿瘤学 | 1987篇 |
出版年
| 2024年 | 32篇 |
| 2023年 | 383篇 |
| 2022年 | 700篇 |
| 2021年 | 1210篇 |
| 2020年 | 764篇 |
| 2019年 | 1016篇 |
| 2018年 | 1088篇 |
| 2017年 | 814篇 |
| 2016年 | 881篇 |
| 2015年 | 927篇 |
| 2014年 | 1203篇 |
| 2013年 | 1445篇 |
| 2012年 | 2128篇 |
| 2011年 | 2155篇 |
| 2010年 | 1120篇 |
| 2009年 | 936篇 |
| 2008年 | 1388篇 |
| 2007年 | 1306篇 |
| 2006年 | 1213篇 |
| 2005年 | 1054篇 |
| 2004年 | 896篇 |
| 2003年 | 759篇 |
| 2002年 | 659篇 |
| 2001年 | 100篇 |
| 2000年 | 81篇 |
| 1999年 | 89篇 |
| 1998年 | 101篇 |
| 1997年 | 92篇 |
| 1996年 | 70篇 |
| 1995年 | 75篇 |
| 1994年 | 50篇 |
| 1993年 | 54篇 |
| 1992年 | 44篇 |
| 1991年 | 40篇 |
| 1990年 | 32篇 |
| 1989年 | 28篇 |
| 1988年 | 40篇 |
| 1987年 | 28篇 |
| 1986年 | 26篇 |
| 1985年 | 19篇 |
| 1984年 | 34篇 |
| 1983年 | 17篇 |
| 1982年 | 27篇 |
| 1981年 | 32篇 |
| 1980年 | 22篇 |
| 1979年 | 11篇 |
| 1978年 | 13篇 |
| 1974年 | 15篇 |
| 1973年 | 12篇 |
| 1972年 | 10篇 |
排序方式： 共有10000条查询结果，搜索用时 0 毫秒
1.
2.
3.
4.
5.
6.
7.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
8.
Marco Maruzzo Umberto Basso Eugenio Borsatti Laura Evangelista Filippo Alongi Orazio Caffo Francesca Maines Sara Galuppo Rocco De Vivo Fable Zustovich Dario Palleschi Andrea Zivi Teodoro Sava Mariella Sorarù Roberto Iacovelli Maurizio Nicodemo Susanne Baier Lucia Fratino Vittorina Zagonel 《Clinical genitourinary cancer》2019,17(1):e187-e194
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献9.
10.